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the expression of collagen type I and III as well as fibronectinRole of glomerular ultrafiltration of growth factors in progres-
in renal interstitial myofibroblasts about 2.5 to 4-fold.sive interstitial fibrosis in diabetic nephropathy.
Conclusions. Proteinuria-induced progressive renal intersti-Background. The present in vivo and in vitro experiments
tial fibrosis may be caused by glomerular ultrafiltration of highwere performed to test the hypothesis that in rats with glom-
molecular weight bioactive growth factors, HGF and TGF-b,erular proteinuria, the bioactive growth factors transforming
which “activate” tubular cells through apical membranes.growth factor-b (TGF-b) and hepatocyte growth factor (HGF)
These apical signals are translated into basolateral events thatare ultrafiltered into tubular fluid, can interact with respective
are recognized by cells in the interstitium, such as the basolat-receptors in apical tubular cell membranes, increase the expres-
eral secretion of the C-C-chemokines MCP-1 and RANTES,sion and basolateral secretion of C-C-chemokines, which inter-
which may (via macrophages) stimulate interstitial myofi-act with cells in the renal interstitium and indirectly cause
broblasts, and thus lead to accumulation of extracellular matrixmyofibroblasts to increase the expression of extracellular ma-
proteins and progressive interstitial fibrosis.trix proteins.
Methods. HGF and TGF-b were measured by Western blot
and bioassay in glomerular ultrafiltrate that was collected by
nephron micropuncture from rats with diabetic nephropathy
Prospective randomized clinical trials indicate thatand control rats. Proximal tubular and collecting duct cells were
glomerular proteinuria is a risk factor for the rate ofincubated with diluted proximal tubular fluid or recombinant
progression of chronic renal failure [1–3]. Moreover, pro-human HGF (rhHGF) or rhTGF-b and expression of C-C-
chemokines was measured by RT-PCR and ELISA. Interac- teinuria tightly correlates with quantitative histologic
tions of tubular cell chemokines with macrophages and indi- measures of interstitial fibrosis [4]. A slowly progressive
rectly with myofibroblasts were also examined using cell culture
macrophage infiltrate is believed to be causally linkedmodels.
to interstitial fibrosis possibly by the secretion of cyto-Results. In rats with glomerular proteinuria due to diabetic
kines that act on interstitial fibroblasts causing the latternephropathy mature, bioactive HGF as well as active and latent
TGF-b were detected in early proximal tubular fluid. Specific to produce increased amounts of extracellular matrix
HGF-and TGF-b type II receptors were expressed in apical [5–9]. This relationship between glomerular proteinuria
tubular membranes more in diabetic compared to control rats.
on one hand, and onset and progression of renal failure,Incubation of cultured mouse proximal tubular cells (mPTC)
early infiltration of macrophages followed by progressiveor medullary collecting duct cells (mIMCD-3) with diabetic rat
proximal tubular fluid increased MCP-1 and RANTES mRNA tubulointerstitial lesions on the other hand has also been
levels as well as secreted peptide up to threefold. In contrast, demonstrated in the most common single cause of end-
high glucose (450 mg/dL), bovine serum albumin (BSA) or rat stage renal disease, namely diabetic nephropathy [6,
albumin (each at 100 mg/mL) or 10 nmol/L insulin-like growth
10, 11].factor-I (IGF-I; which was also present in glomerular ultrafil-
Glomerular proteinuria not only results in ultrafiltra-trate in rats with diabetic nephropathy) did not affect expres-
sion of these chemokines. Recombinant human TGF-b as well tion of serum albumin and globulins, but also of bioactive
as rhHGF each increased MCP-1 and RANTES mRNA as proteins that are normally not present in proximal tubu-
well as peptide levels several-fold. In cultured macrophages lar fluid, due to their high molecular weight forms in
MCP-1 raised the secretion of TGF-b, which in turn increased
serum that prevent their glomerular ultrafiltration. For
example, insulin-like growth factor-I (IGF-I), which is
present in serum in 50 and 150 kD molecular forms, isKey words: diabetic nephropathy, proteinuria, TGF-b, hepatocyte
growth factor, MCP-1, fibronectin. not or only minimally ultrafiltered in normal glomeruli,
but undergoes glomerular ultrafiltration in the experi-Received for publication March 25, 1999
mental nephrotic syndrome in rats [12] and in streptozo-and in revised form September 21, 1999
Accepted for publication October 12, 1999 tocin-induced diabetic renal disease [13]. Moreover, ul-
trafiltered IGF-I activates IGF-I receptors that areÓ 2000 by the International Society of Nephrology
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expressed in apical tubular membranes resulting in tubu- Streptozotocin 85 mg/kg (Sigma, St. Louis, MO, USA).
lar action of ultrafiltered IGF-I [12–14]. In addition to Subsequently, rats received daily subcutaneous injec-
IGF-I receptors, tubular cells in different segments of tions of insulin, 1 to 5 IU/day, to maintain blood glucose
the nephron also express other signaling receptors in levels at 300 to 350 mg/dL. Blood glucose was measured
apical membranes. These may include p190met (hepato- weekly in tail blood with a glucometer (Encoree, Bayer
cyte growth factor receptor) and TGF-b receptors (ab- Corporation, Elkhart, IN, USA) and insulin dose was
stract; Fervenza et al, J Am Soc Nephrol 8:586, 1997) adjusted as necessary. Animals had free access to water
[15]. The respective ligands, hepatocyte growth factor and rat chow. Control rats were housed under similar
(HGF) and transforming growth factor-b (TGF-b), are conditions.
present in serum in high molecular weight forms. HGF, Nephron micropuncture. At 24 to 30 weeks of diabe-
which is probably largely of hepatic origin, is present in tes, the animals underwent nephron micropuncture to
serum as bio-inactive monomeric ProHGF (97 kD) and extensively collect proximal tubular fluid using protocols
as mature, heterodimeric HGF (80 to 92 kD) [16]. TGF-b published previously from this laboratory with minor
is also found in serum in considerable amounts, and large modifications [18]. During micropuncture, the animals
stores are present in platelets that release the peptide received Ringer’s saline corresponding to 0.5% body
upon degranulation [17]. However, in serum and plate- weight per hour. Tubular fluid was collected from early
lets $99% of TGF-b is not present in the mature, di- proximal tubules, placed under mineral oil and stored
meric, bioactive form (25 kD), but it is bio-inactive due at 2808C until used in assays or experiments. At the
to binding to latency associated peptide (LAP, approxi- end of the micropunture collections, arterial blood was
mately 100 kD), binding in a tertiary protein complex obtained from some rats, kidneys were removed and 1
of latency associated peptide (LAP) and latent TGF-b to 2 mm coronal slices were fixed in 4% performaldehyde
binding protein (LAP-LTBP, 220 kD) or association with for immunohistological studies.
a2-macroglobulin (approximately 900 kD). Due to their
Immunohistological studieshigh molecular weight forms of serum HGF and TGF-b,
these two proteins would not be expected to be ultrafil- Expression of p190met (HGF-receptor) and TGF-b type
tered in normal glomeruli, but in proteinuric states they II receptors. Expression of p190met and TGF-b type II
may be translocated into proximal tubular fluid. receptors was examined in diabetic and control rat kid-
The present studies were performed to test the hypoth- neys by immunohistochemistry on 5 mm coronal kidney
esis that glomerular proteinuria such as in diabetic ne- sections using rabbit IgG antibody against p190met (1:200)
phropathy allows for glomerular ultrafiltration of HGF and rabbit IgG against rat TGF-b type II receptors
and TGF-b. Both growth factors in tubular fluid interact (1:200; both from Santa Cruz Biotechnology, Santa Cruz,
with apical tubular cell receptors to cause tubular cell CA, USA). Bound antibody was visualized using biotin-
activation resulting in increased basolateral secretion of ylated second antibody and avidin-horseradish peroxi-
bioactive molecules such as C-C-chemokines, which in- dase (HRPO) supplied as a commercially available kit
teract with macrophages and indirectly with myofi- (Histostain-Plus, Zymed Laboratories, South San Fran-
broblasts to increase expression of extracellular matrix cisco, CA, USA) and the techniques recommended by
proteins. This may be a pathogenetic link between glo- the manufacturer.
merular injury and subsequent tubulointerstitial pa-
thology. Western blot analysis of HGF in
glomerular ultrafiltrate
Hepatocyte growth factor was analyzed in sera, urineMETHODS
and proximal tubular fluid that was collected by micro-To examine the above hypothesis, a series of in vivo
puncture from control and diabetic rats by Western blot.and in vitro experiments were performed. Glomerular
Sera (1 mL/lane, N 5 8), pooled proximal tubular fluidultrafiltrate was collected extensively from rats with dia-
(3 mL/lane, N 5 4), and urine (3 mL/lane, N 5 4) werebetic nephropathy and control animals to measure the
electrophoresed in 10% sodium dodecyl sulfate-poly-levels of HGF and TGF-b in glomerular ultrafiltrate,
acrylamide gel electrophoresis (SDS-PAGE) minigels inand to examine the effects of ultrafiltered growth factors
15 mL/lane of reducing Laemmli buffer. Urine samplesin tubular cells with respect to basolateral secretion of
were desalted prior to electrophoresis by centrifugationC-C-chemokines [MCP-1; regulated upon activation,
through spin-concentrators with nominal cut-off of 10normal T-cell expressed and secreted (RANTES)] and
kD (Amicon Corporation, Danvers, MA, USA), andinteraction of the latter with renal interstitial cells.
concentrates were reconstituted to the original volume
Animal studies with de-ionized water.
Separated proteins were electrotransferred onto nitro-Thirty-five Sprague-Dawley rats, 120 to 150 g body
weight, were made diabetic with a single injection of cellulose. HGF was visualized by Western blotting with
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specific anti-HGF antibody (1:1000; Santa Cruz Biotech- well or 24-well Anopore support membrane inserts
(Nalge-Nunc, Naparville, IL, USA). In these inserts con-nology), which recognizes an epitope in the a-subunit
using protocols previously published from this labora- fluent cells formed tight monolayers allowing for selec-
tive exposure of apical membranes. At confluence, cul-tory [19].
tures in Anopore supports were tested for leakage with
Assay of TGF-b in proximal tubular fluid and in 3H-mannitol (DuPont-NEN, Boston, MA, USA) which
conditioned media was #2.9% in six hours.
Macrophage chemoattractant protein-1 (MCP-1) mRNATransforming growth factor-b levels were measured in
proximal tubular fluid with a highly specific and sensitive in tubular fluid-conditioned mPTC cells by quantitative
reverse transcribed-polymerase chain reaction (RT-PCR).bioassay, using mink lung epithelial cells stably trans-
fected with a truncated PAI-1 promoter fused to a lucif- Mouse proximal tubule cells (mPTC) in 96-well plates
were serum-starved for 24 hours and then incubated witherase reporter (the cells were kindly donated by Dr. Dan
Rifkin, New York University, New York, NY, USA) FCS-free medium containing pooled, 1:5-diluted diabetic
(N 5 4) or control rat proximal tubular fluid (N 5 4),[20]. Cells were planted in 96-well plates at approxi-
mately 30,000 cells per well in Dulbecco’s modified Ea- 25 ml/well, for 20 hours. Total RNA was extracted from
cultured cells of each well and a commercially availablegle’s medium (DMEM)/F-12 containing 10% FCS and
allowed to attach. Cells were washed three times with RNA isolation reagent (RNA-Stat-60; Tel.:Test Inc.,
Friendswood, TX; USA) and the procedures specifiedDMEM/F-12 containing 0.1% bovine serum albumin
(BSA). Then they were incubated with recombinant hu- by the manufacturer. For RT-PCR, random-primed first-
strand cDNA was synthesized from RNA from each wellman TGF-b1 (rhTGF-b1; R&D Systems, Minneapolis,
MN, USA), 1 to 1000 pg/ml, as standards each in quadru- with a commercial procedure (Boehringer Mannheim,
Indianapolis, IN, USA). Aliquots of cDNA were thenplicate or with proximal tubular fluid that had been col-
lected from control (N 5 6) or diabetic rats (N 5 6) at amplified using specific primers for murine MCP-1,
RANTES and a-actin or GAPDH as the control. The1:10 in medium or with medium alone (blank), 25 mL/
well. Incubations of diluted proximal tubular fluid were primers used were 59-CTCACCTGCTGCTACTCA
TTC-39 (sense) and 59-GCATGAGGTGGTTGTGAAperformed either with (total TGF-b) or without (active
TGF-b) prior heat activation in a water bath at 808C for AAA-39 (antisense) for murine MCP-1, 59-GAAGAT
CTCTGCAGCTGCCCT-39 (sense) and 59-GCTCA10 minutes.
Plates were incubated for 12 hours at 378C; wells were TCATCCAAATAGTTGA-39 (antisense) for murine
RANTES, 59-TCTAGGCACCAAGGTGTG-39 (sense),washed and lyzed with lysate buffer (100 mL/well). Ly-
sates were cleared by microcentrifugation and luciferase 59-TCATGAGGTAGTCCGTCAGG-39 (antisense) for
mouse a-actin, and 59-CCATGGAGAAGGCCGGGG-activity was measured using a commercially available kit
and a Monolight 2010 luminometer (Analytical Lumi- 39 (sense) and 59-CAAAGTTGTCATGGATGACC-39
(antisense) for mouse GAPDH. PCR products werenescence Laboratory, Ann Arbor, MI, USA). Standard
curves were constructed by linear regression analysis and electrophoresed in 4% agarose gels containing 0.5 mg/ml
of ethidium bromide. Resolved gels were photographedr values were between 0.996 and 0.999. Measurements
of secreted TGF-b in medium from WEHI 274.1 cells under UV-light with Polaroid negative film (Polaroid,
Cambridge, MA, USA). Bands were scanned by densi-were also performed with this bioassay.
tometry, and densitometric units for MCP-1 or RANTES
Cell culture experiments mRNA were expressed relative to the a-actin mRNA
of the same sample.Cell cultures. In vitro studies of effects of proximal
tubular fluid, rhHGF and rhTGF-b on C-C-chemokines Proximal tubular fluid-induced secretion of MCP-1
peptide. Mouse proximal tubule cells and mIMCD-3were performed in cultured mouse proximal tubular cells
(mPTC) that had been obtained as a kind gift from Car- cells were incubated with FCS-free DMEM/F-12 or me-
dium containing pooled, 1:5 diluted diabetic rat proximalolyn Kelly, M.D. (UCSD, San Diego, CA, USA) [21] and
mouse inner medullary collecting duct cells (mIMCD-3; tubular fluid (25 ml/well, N 5 4). Cells were incubated
for 20 hours. Conditioned media were aspirated, dilutedATCC, Rockville, MD, USA). WEHI 274.1 cells
(ATCC) were used as a culture model of macrophages 1:4 and MCP-1 was measured by dual-antibody enzyme-
linked immunosorbant assay (ELISA) using a commer-and grew primarily in suspension. NRK-49F cells, which
are rat kidney-derived myofibroblasts (ATCC), express cially available kit and the manufacturer’s instructions
(R&D Systems). This assay is highly sensitive and spe-a-smooth muscle actin as tested in this laboratory and
were used in some of the studies. All cells were grown cific for mouse MCP-1/JE and does not recognize rat
MCP-1.in DMEM/F-12 medium containing 10% fetal calf serum
(FCS) supplemented with penicillin and streptomycin. Effect of HGF- and TGF-b–neutralizing antibodies on
proximal tubular fluid-induced MCP-1 expression inIn some experiments tubular cells were grown in 96-
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mPTC. Additional studies were performed to examine bioassay described above. Total cell protein was mea-
whether or not coincubation of diabetic rat proximal sured with the DC-protein assay using a commercially
tubular fluid with a mixture of neutralizing antibodies available kit and the manufacturer’s instructions (Bio
against TGF-b (5 mg/mL; R & D Systems), TGF-b recep- Rad Laboratories, Hercules, CA, USA).
tor type II (3 mg/mL, Santa Cruz Biotechnology), HGF Transforming growth factor-b–induced increased ex-
(3 mg/mL, Santa Cruz), and HGF receptors (3 mg/ml, pression of extracellular matrix proteins in rat renal in-
Santa Cruz) would block the diabetic rat proximal tubu- terstitial myofibroblasts. Further in vitro studies were
lar fluid-induced increased expression of MCP-1 mRNA performed to obtain evidence for a role of macrophage-
in mPTC cells. Near confluent cells were incubated in derived TGF-b to increase the expression of extracellu-
96-well plates for 24 hours with FCS-free medium (Con- lar matrix proteins in interstitial myofibroblasts. NRK-
trol, N 5 4), medium containing the above antibodies 49F cells were incubated for 48 hours with serum-free
(N 5 4), or medium containing pooled, diluted (1:5) medium containing 0.1% BSA (control, N 5 6) or me-
diabetic rat proximal tubular fluid in the absence (N 5 dium containing 400 pmol/L rhTGF-b1 (N 5 6; R&D
4) or presence (N 5 4) of the mixture of neutralizing Systems). mRNA levels for collagen a2I, collagen a1III,
antibodies. MCP-1 mRNA levels were measured by RT- fibronectin and rat GAPDH were measured by RT-PCR
PCR as described above. as described above using the following primers: 59-TG
Effect of glucose, albumin and growth factors on TTCGTGGTTCTCAGGGTAG-39 (sense) and 59-TT
MCP-1 and RANTES mRNA. In separate experiments GTCGTAGCAGGGTRTCTTTC-39 (antisense) for col-
mPTC cells in 24-well plates were incubated with high lagen a2I; 59-CGAGGTAACAGAGGTGAAAGA-39
glucose medium (450 mg/dL), BSA (100 mg/mL), rat (sense) and 59-AACCCAGTATTCTCCGCTCTT-39 (an-
albumin (100 mg/mL; Sigma), rhIGF-I (10 nmol/L; Gift tisense) for collagen a1III; 59-TTTTGACAACGGGAA
from Chiron Corporation, South San Francisco, CA, GCATTATCAGATAA-39 (sense) and 59-TGATCAA
USA), rhHGF (1 nmol/L; R&D Systems) or rhTGF-b1 AACATTTCTCAGCTATTGG-39 (antisense) for fibro-
(1nmol/L; R&D Systems) for 20 hours, and MCP-1 and nectin, and 59-GACAAGATGGTGAAGGTCGG-39
RANTES mRNA was measured by RT-PCR as de- (sense) and 59-CATGGACTGTGGTCATGAGC-39 (an-
scribed above. tisense) for rat GAPDH.
Effect of tyrosine kinase inhibitors on HGF-induced
MCP-1 in mPTC. To examine whether or not the HGF Statistical analysis
induced MCP-1 secretion in mPTC cells requires activity Data are expressed as mean 6 one standard error of
of tyrosine kinases such as those known to be involved
the mean (SEM). Statistical comparisons were made by
in p190met signaling, mPTC cells were incubated with
Student’s t-test or analysis of variance (ANOVA), fol-FCS-free DMEM/F-12 (control) or medium containing
lowed by the Newman-Keuls Multicomparison test. Cal-1 nmol/L rhHGF in the presence or absence of Wortman-
culations were performed using the Stat-Most versionnin (10 nmol/L; Sigma) or Genistein (100 nmol/L;
2.5 software (Data Most Corporation, Salt Lake City,Sigma), 500 mL/well, N 5 6 each. Cleared conditioned
UT, USA). Probability of less than 5% was defined asmedia were assayed for MCP-1 by ELISA as described
statistically significant.above.
Effects of apical incubation of mPTC and mIMCD-3
cells with rhIGF-I, rhTGF-b and rhHGF on basolateral RESULTS
secretion of MCP-1 and RANTES. The directed (baso- Glomerular ultrafiltration of HGF
lateral vs. apical) secretion of MCP-1 and RANTES after
Western analysis of control and diabetic rat serumapical stimulation with different growth factors was ex-
indicated the presence of ProHGF as well as of matureamined in mPTC and mIMCD-3 cells that were incu-
HGF (Fig. 1). Relative ProHGF levels in diabetic serabated with FCS-free DMEM/F-12 (control) or medium
were 310 6 30% compared to 100 6 21% in sera fromcontaining 10 nmol/L rhIGF-I, 1 nmol/L rhTGF-b1, or
control rats (P , 0.05; N 5 8). HGF-a-chain levels re-1 nmol/L rhHGF, for six hours. MCP-1 and RANTES
flecting mature HGF tended to be greater in diabeticwere measured by ELISA selectively in apical and baso-
compared to control rat sera (134 6 7% and 100 6lateral media.
18%, respectively; P 5 NS). Mature HGF was found inMacrophage chemoattractant protein-1–induced secre-
diabetic but not in control rat urine as indicated by thetion of TGF-b in cultured macrophages. WEHI 274.1
presence of a-subunits in reducing Western blots (Fig.cells were incubated with FCS-free medium containing
1). ProHGF could not be found in the urine of diabetic0.1% BSA in 24-well plates (control, N 5 6), or in me-
nor in control rats. Tubular fluid from diabetic rats con-dium containing rhMCP-1 (R&D Systems), 500 pmol/L
tained mature HGF, but ProHGF appeared to be absent(N 5 6) or 2 nmol/L (N 5 6) for 24 hours. Active and
total TGF-b was measured in cleared media using the from tubular fluid or was present at very low levels not
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Fig. 1. Western blot analysis of hepatocyte
growth factor (HGF) in diabetic mellitus
(DM) and control (CO) rat serum (1 mL/lane),
urine (3 mL/lane) and pooled proximal tubular
fluid obtained by nephron micropuncture (3
mL/lane) under reducing conditions. HGF is
present in serum in diabetic and control rats,
but in urine and proximal tubular fluid HGF
is only found in rats with diabetic nephropathy
but not in normal animals. ProHGF (approxi-
mately 95 kD) levels are increased in serum
from diabetic as compared to control rats.
HGF a-subunits (approximately 69 kD and a
separate band at approximately 54 kD be-
lieved to be a lesser glycosylated form of the
HGF-a-subunit) indicate the presence of ma-
ture, dimeric HGF in diabetic rats in serum,
proximal tubular fluid and urine. In contrast,
in control rats, mature HGF is found in serum
at somewhat lesser levels compared to dia-
betic rats, but is below detectable levels or
absent in normal rat glomerular ultrafiltrate
and urine.
allowing for visualization with the current Western blot
method (Fig. 1).
Glomerular ultrafiltration of TGF-b. Tubular fluid
TGF-b was measured with a quantitative mink lung epi-
thelial cell assay that recognized the peptide specifically
and did not differentiate between different isoforms [20].
However, only TGF-b1 was present in serum [17], sug-
gesting that this was also the only isoform present in the
glomerular ultrafiltrate. This assay not only allowed for
quantitative measurement of TGF-b levels, but at the
same time also recognized its bioactivity. In control rat
tubular fluid, free directly-active TGF-b levels were less
than 10 pg/mL, but very small amounts of inactive TGF-b
were present (Fig. 2). In contrast, significant levels of
both free and total TGF-b were found in diabetic rat
Fig. 2. Transforming growth factor-b (TGF-b) in proximal tubularglomerular ultrafiltrate (Fig. 2).
fluid that was collected from control animals or from rats with diabeticExpression of HGF and TGF-b receptors. The p190met nephropathy by nephron micropuncture (N 5 6). Levels of active (free)
protein that was the receptor for HGF was found in TGF-b ( ) in glomerular ultrafiltrate from control rats are , 10
pg/ml. Active as well as total TGF-b ( ) levels in tubular fluid arevarious segments of the nephron in both normal and
each greater in rats with diabetic nephropathy compared to controlsdiabetic rats. In both groups of animals p190met was ex- (*P , 0.01 for each comparison).
pressed in preglomerular arterioles, distal tubules, con-
necting portions, and cortical and medullary collecting
ducts. There were some differences in HGF-receptor
receptors in apical membranes was greater in diabeticexpression between diabetic and normal rat kidneys (Fig.
(Fig. 3d) than in control rat kidneys (Fig. 3a). Apical3). These included expression of p190met in glomeruli
HGF-receptors was also found in distal tubules and con-(in pericapillary locations and in visceral and parietal
necting portions in diabetic but not in control rats. Inepithelium, Fig. 3c) in diabetic but not in control rats.
collecting ducts apical HGF-receptors were similarlyMoreover, HGF-receptors were expressed in thick as-
found in control and in diabetic rats (Fig. 3b).cending limbs of the loop of Henle in diabetic but not
in control rats. In proximal tubules, expression of HGF- Transforming growth factor-b type II receptors were
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Fig. 3. Expression of p190met (HGF receptor) in control rats (a) and in rats with streptocotocin-induced diabetic nephropathy (b–d ). Major
differences between diabetic and control rats include greater expression in apical membranes in proximal tubules in diabetic rats (d) compared
to control rats (a). Moreover, there is expression of HGF-receptors in diabetic rat glomeruli in pericapillary locations as well as in visceral and
parietal epithelial cells (c).
expressed in control rat kidneys in (pre)glomerular arte- (1 nmol/L) increased the MCP-1 mRNA levels in mPTC
cells 2.5- to 3.5-fold (Fig. 7). In contrast, IGF-I, whichrioles, some proximal tubules and in cortical and medul-
lary collecting ducts (Fig. 4). In diabetic rat kidneys, was also present in diabetic rat tubular fluid [13], did
not increase MCP-1 mRNA levels (Fig. 7). Similarly,TGF-b type II receptors were found in the same locations
as in control animals, but were also weakly expressed in high glucose medium (Fig. 7) or medium containing BSA
or rat albumin at 100 mg/mL did not raise MCP-1 mRNAsome glomeruli in a mesangial distribution (Fig. 4a) and
in apical membranes in distal tubules. Some proximal levels significantly.
These findings suggested that it was the presence oftubules immunostained positive for TGF-b type II recep-
tors (Fig. 4d), more so in basolateral membranes and HGF and TGF-b in glomerular ultrafiltrate that caused
increased secretion of MCP-1, and this was further dem-faintly in some segments in apical membranes. Cortical
and medullary collecting ducts in diabetic rats express onstrated when the action of these two cytokines in tubu-
lar fluid was inhibited. Indeed, incubation of proximalTGF-b type II receptors in apical membranes (Fig. 4b).
Effects of proximal tubular fluid, proteins and growth tubular cells with neutralizing antibodies that prevented
the interaction of HGF and TGF-b with their respectivefactors on tubular cell MCP-1 expression and secre-
tion. Incubation of mPTC cells with pooled, 1:5 diluted receptors abolished the rise in MCP-1 mRNA levels
(Fig. 8).diabetic rat proximal tubular fluid caused about a two-
fold increase in steady-state MCP-1 mRNA levels (P , Recombinant human HGF also induced an increase
in secreted MCP-1 peptide. This effect of HGF was par-0.05; Fig. 5). Moreover, incubation of mPTC as well as
mIMCD-3 cells with diabetic rat proximal tubular fluid tially blunted by coincubation with Wortmannin or Gen-
istein, respectively (Fig. 9). Since Genistein inhibitedraised the secretion and accumulation of MCP-1 peptide
in medium about three- to fourfold (P , 0.05 for each several tyrosine kinases and Wortmannin (semi) specifi-
cally inhibited phosphatidyl-inositol-39-kinase, thesecomparison; Fig. 6). Both rhTGF-b1 and rhHGF
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Fig. 4. Transforming growth factor-b (TGF-b) type II receptors in rats with streptocotocin-induced diabetic nephropathy (a and b) and in control
rats (c and d ). TGF-b type II receptors are seen in the mesangium in diabetic but not in control rats. Cortical collecting duct apical membranes
express TGF-b type II receptors in both diabetic and control rats. Some, but not all, proximal tubules are positive for TGF-b type II receptors
and there appears to be no difference between diabetic and control rats (c, d).
findings suggest that HGF induced increased MCP-1 pro- expression and secretion. rhHGF (1 nmol/L) increased
RANTES mRNA levels in mPTC and mIMCD-3 cellsduction through receptor signaling involving tyrosine ki-
nases in general and phosphatidyl-inositol-39-kinase in about four- and twofold, respectively (P , 0.05, each;
Fig. 11). Equimolar levels of rhTGF-b tended to increaseparticular.
Additional experiments were performed to demon- RANTES mRNA in proximal tubular cells (P 5 0.070)
and significantly increased its expression in mIMCD-3strate that apical stimulation of mPTC and mIMCD-3
cells with rhHGF or rhTGF-b1 (1 nmol/L) caused in- cells (P , 0.05, Fig. 11). Similar to MCP-1, RANTES
was also secreted primarily through basolateral mem-creased basolateral secretion of MCP-1. These studies
were performed in mPTC and mIMCD-3 cells that were branes in the basal state as well as after stimulation with
apical rhHGF or rhTGF-b1 (Fig. 12).grown to confluence on Anopore support membranes.
Under control conditions as well as during incubation MCP-1 raises TGF-b secretion by macrophages. Incu-
bation of WEHI 274.1 macrophages with rhMCP-1 in-with growth factors, about two-thirds of MCP-1 were
secreted basolaterally. Apical TGF-b and even more so creased the release of TGF-b into culture medium (Fig.
13). About one-quarter to one-fifth of macrophage-HGF increased MCP-1 secretion without changing the
apical/basolateral distribution of secretion (Fig. 10A). derived TGF-b was directly bioactive. Since macro-
phages also expressed TGF-b in their basic unstimulatedIn mIMCD-3 cells there was also a preference towards
basolateral secretion of MCP-1 (Fig. 10B). Both TGF-b stage, the accumulation of macrophages itself raised the
levels of interstitial TGF-b in vivo and were further in-and HGF significantly increased the amount of basolat-
erally secreted MCP-1. creased by tubular cell-derived MCP-1.
TGF-b induced extracellular matrix proteins in renalEffects of HGF and TGF-b on tubular cell RANTES
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Fig. 7. Effects of high glucose medium (Gluc) and recombinant growth
factors on MCP-1 mRNA levels in mouse proximal tubular cells. mPTCsFig. 5. Effect of pooled glomerular ultrafiltrate from control and dia-
were grown in 24-well plates and incubated for 24 h with FCS/BSA-betic rats on monocyte chemoattractant protein-1 (MCP-1) mRNA in
free DMEM/F-12 medium (Control, CO), medium containing high glu-mouse proximal tubular cells (mPTCs). Cells were grown in 96-well
cose, 450 mg/dL (Gluc), or 10 nmol/L rhIGF-I, 1 nmol/L rhTGF-b1, orplates and incubated (24 h) with pooled proximal tubular fluid from
1 nmol/L rhHGF. Data are expressed as ratios of MCP-1 mRNA/rats with diabetic nephropathy (N 5 4) or control animals (N 5 4)
a-actin mRNA as multiples of control in percentage (*P , 0.05 vs.at 1:5 in FCS/BSA-free DMEM/F-12 medium. MCP-1 levels were
control).measured by RT-PCR and normalized for a-actin mRNA levels
(*P , 0.05).
Fig. 8. Inhibition of MCP-1 expression in mPTCs by antibodies that
neutralize the action of HGF and TGF-b. Cells were grown in 96-well
plates and incubated with FCS-free DMEM/F-12 (Control, Co, N 5
4), medium containing a mixture of neutralizing antibodies against
HGF, TGF-b, HGF-receptors and TGF-b type II receptors (Co 1Fig. 6. Effect of diabetic rat proximal tubular fluid on secreted mono-
AB, N 5 4), pooled proximal tubular fluid (1:5) that was obtained bycyte chemoattractant peptide-1 (MCP-1) in mouse proximal tubular cells
micropuncture from rats with diabetic nephropathy in the absence (PTF,(mPTC) and mouse inner medullary collecting duct cells (mIMCD-3).
N 5 3) or presence (PTF 1 AB, N 5 3) of the mixture of neutralizingCells were incubated with ( ) or without ( ) pooled, diluted early
antibodies. *P , 0.05.proximal tubular fluid from rats with diabetic nephropathy (*P , 0.05).
DISCUSSIONmyofibroblasts. Macrophage-derived TGF-b likely acts
The current studies demonstrate that HGF andon interstitial myofibroblasts in vivo. The effects of this
TGF-b, which are both present in plasma in high molecu-interaction were examined using an in vitro model of rat
lar weight forms, are translocated into tubular fluid inrenal interstitial myofibroblasts. Incubation of NRK-49F
proteinuric glomerular states such as experimental dia-cells with rhTGF-b1 (400 pmol/L) raised the expression
betic nephropathy, the model used in the present experi-of interstitial extracellular matrix proteins collagen a2I,
ments. Both growth factors may reach early proximalcollagen a1III and fibronectin about 2.5- to fourfold, re-
spectively (P , 0.05 each; data not shown). tubules exclusively by glomerular ultrafiltration of plasma,
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Fig. 9. Effects of the tyrosine-kinase inhibitor, Genistein, and the phos-
phatidyl-inositol-39-kinase inhibitor, Wortmannin, on HGF-induced
MCP-1 secretion in mPTCs. Cells in 24-well plates were incubated
with FCS/BSA-free DMEM/F-12 medium (Control; (h), or medium
containing Genistein (j) or Wortmannin ( ) in the presence or ab-
sence of 1 nmol/L rhHGF. Levels of accumulated MCP-1 in medium
were measured with a specific ELISA. Wortmannin and Genistein each
reduce the rhHGF-induced secretion of MCP-1 (*P , 0.05 compared
to HGF-baseline, respectively).
but may also, in part, originate from synthesis and secre-
tion by residential glomerular cells. Results from these
studies also indicate that either both cytokines are al-
ready or become bioactive in tubular fluid, although the
Fig. 10. Effect of growth factors on apical or basolateral secretion ofmechanisms for activation remain unclear. HGF in tubu-
MCP-1 in mPTC-cells (A) or mIMCD-3 cells (B). Cells were incubated
lar fluid appears to be largely or exclusively active and in Anopore membrane supports in 24-well plates with FCS/BSA-free
DMEM/F-12 medium in the bottom (basolateral) compartment andmature HGF, since 97 kD ProHGF could not be demon-
medium without (Control) or with addition of 10 nmol/L rhIGF-I, 1strated in tubular fluid Western blots. Perhaps the tubu-
nmol/L rhTGF-b1, or 1 nmol/L rhHGF in the upper (apical) compart-lar fluid ProHGF levels are too low to be visualized ment (N 5 6 each). Accumulated MCP-1 in apical ( ) and basolateral
( ) medium was measured by specific ELISA; *P , 0.05 vs. respectivewith this method. It is also possible, but unproven, that
control.ProHGF is ultrafiltered but becomes quickly activated
in proximal tubular fluid. Naldini and coworkers demon-
strated that urokinase activates ProHGF by specific, lim-
ited proteolysis [22]. Urokinase is expressed by proximal authors found the greatest apical density of HGF-recep-
tubules and is abundantly secreted into tubular fluid tors in proximal tubules. Widespread TGF-b receptor
[23, 24]. expression in the nephron has also been reported by
TGF-b that is present in proximal tubular fluid is, in Ando and coworkers [15]. The present studies confirm
part, bioactive as indicated with the mink lung epithelial some of these previous findings, and indicate expression
cell bioassay. Activation of “latent” TGF-b that is specifically in apical membranes in some nephron seg-
ultrafiltered in inactive forms may occur with down- ments making receptors accessible to their ligands that
stream travel of tubular fluid, such as by fluid acidifica- are present in tubular fluid. In contrast to the previous
tion and/or increased urea concentration, or possibly by report by Ando et al [15], in the present studies immuno-
certain proteases such as urokinase or thrombospondin-1 staining for TGF-b type II receptors in proximal tubules
[25, 26]. is rather faint. However, cultured proximal tubular cells
Specific receptors are accessible to both ultrafiltered express TGF-b type II receptors as indicated by their
growth factors because they are (also) expressed in apical sensitive response to TGF-b. The presence of apical tu-
tubular membranes. This has previously been demon- bular membrane HGF receptors and TGF-b receptors
strated for IGF-I and IGF-II receptors [12, 27–29]. The in normal rats suggests that very small amounts of the
present studies indicate that HGF-receptors (p190met) respective ligands are also present in normal rat glomeru-
are also apically expressed in several segments of the lar ultrafiltrate. The findings from the present studies do
nephron, confirming findings by Fervenza and associates not exclude this possibility.
Urinary excretion of TGF-b is increased in patients(abstract; J Am Soc Nephrol 8:586, 1997). These latter
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Fig. 11. Effects of recombinant human TGF-b (1 nmol/L) and HGF
(1 nmol/L) on the expression of RANTES in mPTC (A) and mIMCD-3
cells (B) (N 5 6 each; *P , 0.05 vs. control).
Fig. 13. Basal (control) and rhMCP-1–stimulated secretion of active
(A) and total TGF-b (B) in cultured macrophages (WEHI 274.1)
(*P , 0.05 vs. control).
the development of interstitial fibrosis in glomerular dis-
eases.
Interaction of ultrafiltered HGF and TGF-b through
apical membranes in different segments of the nephron
“activates” tubular cells, that is, the interaction increases
basolateral secretion of C-C-chemokines. Glomerular ul-
Fig. 12. Basolateral (j) versus apical ( ) secretion of RANTES pep-
trafiltrate from diabetic rats also contains significant lev-tide in mIMCD-3 cells upon apical incubation with recombinant human
HGF (1 nmol/L) and TGF-b (1 nmol/L). In the baseline state (control) els of IGF-I [13]. However, as demonstrated in the pres-
as well as after apical stimulation with the two cytokines the majority ent series of experiments, this growth factor does notof RANTES is secreted basolaterally (*P , 0.05 vs. respective control).
contribute to tubular fluid-induced increased MCP-1
production in tubular cells. Moreover, neither bovine
nor rat serum albumin at levels of these proteins in tubu-
lar fluid in experimental nephrosis or diabetic nephropa-with overt diabetic nephropathy [30], and clinical studies
thy [12, 13] induce increased MCP-1 secretion in culturedin membranous nephropathy have shown that increased
tubular cells. Wang and associates found that bovineurinary TGF-b levels predict subsequent interstitial fi-
brosis one year later [31]. These findings support the serum albumin at 100-fold the concentration used in the
present studies induces increased expression of MCP-1notion that ultrafiltered TGF-b is causatively linked to
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in proximal tubular cells [32]. However, this albumin that contribute substantially to interstitial fibrosis, namely
collagen types I and III and fibronectin.concentration exceeds the levels in proximal tubular fluid
Direct apical interaction of ultrafiltered HGF andin the nephrotic syndrome by one to two orders of magni-
TGF-b may also increase tubular cell expression of inter-tude [12, 13]. In addition, high glucose does not contrib-
stitial extracellular matrix proteins. However, there isute to tubular cell activation as shown in the present
evidence from many experimental and histologic obser-studies. The fact that HGF and TGF-b in tubular fluid
vations that most extracellular matrix proteins in renalare nonredundantly the main or exclusive inducers of
interstitial scars are derived from myofibroblasts. More-MCP-1 is further shown in neutralization experiments.
over, TGF-b that is secreted from interstitially accumu-Antibodies that neutralize the activity of these two cyto-
lating macrophages appears to be a major inducer of thiskines in glomerular ultrafiltrate block the rise in MCP-1
fibroblast activity. Hence, proteinuria-associated apicalexpression and most likely secreted MCP-1 peptide in
biologic signals appear to be translated into basolateralcultured tubular cells. Rovin, Doe and Tan examined
responses recognized by cells in the interstitium. Thesethe urinary excretion of MCP-1 in patients with a variety
basolateral signals include MCP-1 and RANTES thatof proteinuric glomerulopathies and in normal subjects
act on macrophages.[33]. These investigators demonstrated far increased uri-
The relative contribution of each of the growth factors,nary MCP-1 levels in proteinuric states, and particularly
HGF and TGF-b, in proximal tubular fluid to tubularhigh levels were found in diabetic nephropathy. These
cell responses and basolateral C-C-chemokine secretionauthors also convincingly demonstrated that urinary
is unclear, but findings from the current studies indicateMCP-1 originates from tubular secretion. Indeed, as
contributions from both growth factors. In recent in vivoshown in the current experiments, aliquots of MCP-1
studies in mice with spontaneous glomerular and intersti-(and RANTES) that is induced in tubular cells by ultrafi-
tial fibrosis, Mizuno and associates demonstrated thatltered HGF and TGF-b is secreted through apical mem-
exogenous, pharmacological administration of rhHGFbranes and would be expected to undergo urinary excre-
for several weeks prevents or postpones the develop-tion in vivo.
ment of renal fibrosis [41]. Moreover, in vitro studies inObservations in humans as well as studies in experi-
tubular cells in this laboratory indicate that rhHGFmental animal models of inflammatory and noninflama-
blocks collagen type III expression at high (pharmaco-tory glomerular diseases have indicated that increased
logic) but not low concentrations, and does not block thenumbers of macrophages accumulate in the renal inter-
expression of several other extracellular matrix (ECM)stitium prior to the development of interstitial fibrosis,
proteins such as fibronectin (manuscript in preparation).and onset of this macrophage infiltrate is preceded by
In contrast, mice transgenic for HGF develop premature
glomerular proteinuria [3, 9, 34, 35]. Migration of macro-
renal interstitial fibrosis and glomerular sclerosis, sup-
phages into the renal interstitium is also found in diabetic porting a pro-fibrotic role of HGF [42]. Perhaps HGF
nephropathy [6]. Moreover, in patients with diabetic re- has antifibrotic activity at pharmacologic levels, but not
nal disease, macrophages are excreted with urine [10]. at levels observed endogenously.
MCP-1 and RANTES chemokine gradients induce trans- In summary, the present studies indicate that glomeru-
migration of macrophages [36–38]. Both chemokines are lar proteinuria causes translocation of HGF and TGF-b
normally expressed at low levels by tubular epithelium into glomerular ultrafiltrate, where they can “activate”
in several different segments of the nephron. In renal tubular cells through apical membranes, resulting in ba-
biopsy tissue from patients with glomerular diseases solateral secretion of MCP-1 and RANTES. These C-C-
causing gross proteinuria, tubular MCP-1 expression is chemokines may attract macrophages in the peritubular
greatly increased and correlates well with increased num- interstitium. MCP-1 also raises TGF-b secretion in mac-
bers of interstitial macrophages [38]. rophages that acts on myofibroblasts to cause increased
Interstitial macrophages constitutionally express expression of interstitial collagens and fibronectin. This
TGF-b. In fact, macrophages may be the most important chain of events may be an important mechanism through
source of interstitial TGF-b. Findings from the present which glomerular proteinuria causes or contributes to
studies indicate that (tubular cell-derived) MCP-1 fur- the formation of interstitial fibrosis and progressive renal
ther raises TGF-b secretion by macrophages. The most failure.
likely and arguably most important target for macro-
phage-derived TGF-b are interstitial myofibroblasts be- ACKNOWLEDGMENTS
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